Avita Medical Inc.
RCEL evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $340.8M
- Lead Asset:
- cohealyx (Approved)
What it means
What to watch
Prepared research question
What matters most for RCEL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RCEL
Avita Medical (RCEL) is a publicly traded wound-care company that develops and markets autologous cell-harvesting systems and biosynthetic wound matrices, with approved products including the RECELL System, PermeaDerm, and Cohealyx.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 4 of 6 signals
Market Cap
$340.8M
Cash Runway
—
Lead Asset
cohealyx (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates for Avita Medical Inc..
Avita Medical (RCEL) is a publicly traded wound-care company that develops and markets autologous cell-harvesting systems and biosynthetic wound matrices, with approved products including the RECELL System, PermeaDerm, and Cohealyx.
- Cash & equivalents of $9.1M as of 2026-06-30 [sec]
- Net income of -$7.7M as of 2026-06-30 [sec]
- Shareholders' equity of -$27.8M as of 2026-06-30 [sec]
- Second-quarter 2026 revenue of $21.7M, up 18% year-over-year [news]
- PermeaDerm-I study met primary endpoint, showing 70% cost reduction vs. allograft [news]
What works
- PermeaDerm-I study demonstrated a 70% economic advantage over allograft with comparable clinical outcomes, supporting a strong value proposition [news]
- Second-quarter 2026 revenue grew 18% year-over-year to $21.7M, indicating commercial momentum [news]
- Company targets cash flow breakeven in Q4 2026, suggesting a clear path to profitability [news]
What to weigh
- Shareholders' equity is negative at -$27.8M as of 2026-06-30, indicating accumulated losses exceed contributed capital [sec]
- Net loss of -$7.7M as of 2026-06-30 shows the company remains unprofitable [sec]
- Cash & equivalents of only $9.1M as of 2026-06-30 may limit operational runway without additional financing [sec]
From the filings
Quoted directly from source documents.
PermeaDerm-I study met primary endpoint with 70% cost reduction
“Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)”
News · August 18, 2026
Second-quarter 2026 revenue of $21.7M, up 18% year-over-year
“Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier”
News · August 16, 2026
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$27.8M as of 2026-06-30 indicates the company has accumulated losses exceeding contributed capital [sec]
- Limited cash runway — Cash & equivalents of only $9.1M as of 2026-06-30 may constrain operations without additional financing [sec]
- Continued net losses — Net loss of -$7.7M as of 2026-06-30 shows the company is not yet profitable [sec]
What to watch
- Progress toward Q4 2026 cash flow breakeven target [news]
- Commercial adoption and reimbursement trends for PermeaDerm following positive study results [news]
- Revenue growth trajectory, especially sequential quarterly increases [news]
- Any changes in cash position or financing activities given limited cash reserves [sec]
Sources: News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Avita Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avita Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$8M
Lead: Approved
4 candidates
No upcoming catalysts tracked
11 buys · 0 sells (180d)
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 11.2%
- Days to cover
- 15.7
- Shares short
- 3,417,316
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RCEL short interestGovernance
Frequently asked questions
What is the AI investment thesis for Avita Medical Inc.?
Avita Medical (RCEL) is a publicly traded wound-care company that develops and markets autologous cell-harvesting systems and biosynthetic wound matrices, with approved products including the RECELL System, PermeaDerm, and Cohealyx.
What is Avita Medical Inc.'s lead drug candidate?
Avita Medical Inc.'s most advanced tracked candidate is cohealyx (Approved) for Wound bed preparation for full-thickness wounds.
Who is the CEO of Avita Medical Inc.?
Mr. Cary G. Vance is the chief executive officer of Avita Medical Inc. (RCEL).
Where is Avita Medical Inc. headquartered?
Avita Medical Inc. (RCEL) is headquartered in Valencia, CA, United States.
What therapeutic areas does Avita Medical Inc. focus on?
Avita Medical Inc. develops therapies across Immunology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.